BD PharmingenTM PE Mouse Anti-Human MIP-1beta

Description

Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Show More Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Show More Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control. Expression of MIP-1beta by stimulated human monocytes. Human PBMC were stimulated with human IFN-gamma 20 ng/ml final concentration; Cat. No. 554616/554617 for one hour followed by overnight stimulation with LPS 1 mug/ml final concentration; Sigma, Cat. No. L-8272 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, fixed, permeabilized, and stained with 0.03 mug of PE Mouse Anti-Human MIP-1beta Cat. 550078/561120; Left Panel following Pharmingens staining protocol. The data reflects gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, binding by the PE Mouse Anti-Human MIP-1beta antibody was blocked by preincubation with recombinant human MIP-1beta 0.25 mug; Middle panel and by preincubation of the fixed/permeabilized cells with excess unlabeled D21- 1351 antibody 5 mug; custom order; Right panel prior to staining with PE Mouse Anti-Human MIP-1beta. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control and verified using the unlabeled antibody blocking control.